Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 23 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.90 Insider Own19.34% Shs Outstand131.69M Perf Week52.55%
Market Cap1.11B Forward P/E159.03 EPS next Y0.05 Insider Trans0.00% Shs Float106.65M Perf Month36.60%
Income-119.03M PEG- EPS next Q-0.02 Inst Own86.15% Short Float6.40% Perf Quarter69.57%
Sales288.94M P/S3.82 EPS this Y-139.99% Inst Trans-0.48% Short Ratio3.32 Perf Half Y-20.91%
Book/sh3.94 P/B2.12 EPS next Y538.15% ROA1.09% Short Interest6.83M Perf Year-39.55%
Cash/sh4.38 P/C1.91 EPS next 5Y- ROE4.80% 52W Range4.52 - 16.90 Perf YTD27.63%
Dividend Est.- P/FCF6.79 EPS past 5Y-37.53% ROI-10.62% 52W High-50.53% Beta-0.23
Dividend TTM- Quick Ratio8.33 Sales past 5Y57.89% Gross Margin47.80% 52W Low84.96% ATR (14)0.55
Dividend Ex-Date- Current Ratio8.96 EPS Y/Y TTM-153.82% Oper. Margin-3.97% RSI (14)76.55 Volatility8.80% 7.12%
Employees610 Debt/Eq1.18 Sales Y/Y TTM-67.28% Profit Margin-41.19% Recom1.58 Target Price9.16
Option/ShortYes / Yes LT Debt/Eq1.16 EPS Q/Q-386.39% Payout0.00% Rel Volume12.56 Prev Close5.11
Sales Surprise15.17% EPS Surprise186.96% Sales Q/Q-63.78% EarningsFeb 22 AMC Avg Volume2.06M Price8.36
SMA2050.73% SMA5038.20% SMA200-8.08% Trades Volume25,847,526 Change63.60%
Date Action Analyst Rating Change Price Target Change
Dec-12-23Upgrade BofA Securities Neutral → Buy $10 → $8
Aug-08-23Downgrade KeyBanc Capital Markets Overweight → Sector Weight
May-23-23Downgrade Credit Suisse Outperform → Neutral $18 → $14
May-09-23Downgrade Goldman Buy → Neutral
Jan-05-23Downgrade UBS Buy → Neutral $20 → $16
Dec-14-22Initiated Deutsche Bank Buy $25
Dec-07-22Initiated RBC Capital Mkts Outperform $22
Nov-03-22Downgrade BofA Securities Buy → Neutral $32 → $17
Aug-25-22Initiated Credit Suisse Outperform $34
Aug-05-21Resumed Credit Suisse Outperform $44
Feb-23-24 12:15PM
Feb-22-24 08:30PM
08:00AM Loading…
Feb-21-24 08:00AM
Feb-13-24 08:30AM
Feb-11-24 05:00PM
Feb-07-24 06:46AM
Jan-29-24 08:00AM
Dec-18-23 05:27AM
Nov-24-23 08:39AM
Nov-09-23 08:15AM
Nov-08-23 04:02PM
04:49PM Loading…
Nov-07-23 04:49PM
Nov-02-23 06:47AM
Oct-20-23 12:08PM
Oct-17-23 08:15AM
Sep-29-23 12:43PM
Sep-25-23 08:49AM
Sep-19-23 09:31AM
Sep-05-23 04:15PM
Aug-23-23 08:15AM
Aug-22-23 08:14AM
Aug-09-23 04:15PM
Aug-08-23 06:20AM
01:30AM Loading…
Aug-07-23 04:05PM
Jul-27-23 04:05PM
Jul-24-23 04:05PM
Jul-20-23 04:05PM
Jul-18-23 08:37AM
Jul-16-23 08:51AM
Jun-06-23 08:00AM
May-24-23 08:10AM
May-09-23 12:49PM
May-08-23 05:35PM
Apr-17-23 04:15PM
Mar-28-23 05:00PM
Mar-20-23 06:50AM
Mar-13-23 08:45AM
Mar-09-23 06:40AM
Mar-08-23 08:00AM
Mar-04-23 08:19AM
Mar-02-23 08:45AM
Feb-27-23 05:35AM
Feb-23-23 01:00AM
Feb-22-23 05:55PM
Feb-16-23 10:01AM
Feb-15-23 10:00AM
Feb-14-23 04:33PM
Feb-07-23 10:15AM
Feb-06-23 07:34AM
Feb-01-23 08:00AM
Jan-27-23 09:37AM
Jan-16-23 08:30AM
Dec-12-22 09:53AM
Dec-01-22 04:01PM
Nov-28-22 08:30AM
Nov-16-22 05:05PM
Nov-09-22 07:16AM
Nov-07-22 04:10PM
Nov-06-22 07:30AM
Nov-03-22 04:05PM
Nov-02-22 06:15PM
Oct-29-22 08:45AM
Oct-24-22 10:39AM
Oct-19-22 08:10AM
Oct-18-22 04:15PM
Oct-13-22 08:32PM
Oct-08-22 08:28AM
Oct-06-22 11:28AM
Oct-03-22 04:05PM
Sep-13-22 08:00AM
Aug-29-22 01:47PM
Aug-17-22 08:42AM
Aug-15-22 04:05PM
Aug-05-22 01:30PM
Aug-04-22 05:55PM
Aug-02-22 10:00AM
Jul-28-22 10:03AM
Jul-23-22 05:58AM
Jul-22-22 05:49AM
Jul-21-22 02:13PM
Jul-19-22 08:00AM
Jul-13-22 11:11AM
Jul-06-22 04:05PM
Maravai Lifesciences Holdings, Inc. is a life sciences company. It is engaged in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. The firm operates through the following segments: Nucleic Acid Production, Biologics Safety Testing, and Protein Detection. The Nucleic Acid Production segment focuses on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers' research, therapeutic and vaccine programs. The Biologics Safety Testing segment focuses on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. The Protein Detection segment is engaged in manufacturing and selling labeling and visual detection reagents to scientific research customers for their tissue-based protein detection and characterization needs. The company was founded by Eric Tardif and Carl W. Hull in March 2014 and is headquartered in San Diego, CA.